Skip to main content

June 2025

Crack GPAT — Prepare for GPAT Online 

Applications are invited for Pharmacist at Child Care Institution

Compounder / pharmacist / having diploma in Ayurveda / homeopathic / Unani from the institution recognized by govt, of India.
IIT Hyderabad Hiring Doctoral Research Fellow, Pay Rs. 70,680 to Rs 85,000 per month
Ph.D. in Environmental Engineering, Biotechnology, Microbiology, Chemical Engg, Climate Change or other allied areas.  Experience with handling chromatography instruments preferred. 
Online Interview for Project Associate at NIAB
Masters degree in Natural or Agricultural Sciences, MVSc or Bachelors in Engineering or Technology or Medicine from recognized University or equivalent.
Alembic Pharma hiring Product Executive - B.Pharm with MBA Apply
Expertise in Cardio-Diabetic, CNS, or Oncology. Brand lifecycle management; launch and scale. Strong grasp of international regulatory dynamics.
Interview for B.Pharm Fresher in Production at Ipca Laboratories
Operation and supervision of Compression, Granulation & Coating machine i.e. Fette, Glatt, Ganson, Imprinting etc.
Gufic Biosciences Walk in Drive for M.Pharm, B.Pharm, MSc in Production, QA, QC - Freshers can apply
M.Pharm, B.Pharm, M.Sc ; Knowledge of Instruments like HPLC, UPLC, GC, UV, Knowledge of AMV & Reviewer.
Hiring B.Pharm, MSc, BSc candidates in QC, Production at APITORIA PHARMA
Hiring Candidates for APITORIA PHARMA PRIVATE LIMITED (100% subsidary of Aurobindo Pharma Limited) Hyderabad Cluster to fill the following Positions in API Division.
Multiple openings for M.Pharm, B.Pharm, MSc at Nitin Lifesciences Ltd
M.Pharm, B.Pharm, M.Sc, B.Sc ; Nitin is a rapidly growing Indian pharmaceutical company with a strong presence in Injectable manufacturing.
Bharat Biotech to advance GSKs Shigella vaccine candidate
Bharat Biotech International Limited (BBIL) has entered into a licensing agreement with GSK plc to take over the development of altSonflex1‑2‑3, GSK’s promising Shigella vaccine candidate.
Fabhalta® demonstrates Significant Hemoglobin Improvement in New PNH Patient Population
Novartis announced promising results from its Phase IIIB APPULSE-PNH study, evaluating the twice-daily oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria